SCHEDULE 13G/A: Janus Henderson Group Discloses 10.3% Stake in Mirum Pharmaceuticals

Investment giant Janus Henderson Group plc has reported a 10.3% beneficial ownership stake in Mirum Pharmaceuticals, Inc., as detailed in its latest Schedule 13G Amendment No. 5 filing with the SEC.

Summary

• Janus Henderson Group plc reported beneficial ownership of 5,081,957 shares of Mirum Pharmaceuticals, Inc. common stock as of May 30, 2025.
• This stake represents 10.3% of the total outstanding common stock of Mirum Pharmaceuticals, Inc.
• The filing is an Amendment No. 5 to a previous Schedule 13G, indicating an update to their reported ownership position.
• Janus Henderson Group plc, along with its indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML, holds these shares with shared voting and shared dispositive power.
• The reporting person certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Mirum Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance data to indicate positive or negative sentiment regarding the issuer's operations or financial health. It simply states a significant passive investment.

Positives

• A significant institutional investor, Janus Henderson Group plc, holds a substantial 10.3% stake, which can be interpreted by the market as a vote of confidence in Mirum Pharmaceuticals, Inc.
• The investment is stated to be for ordinary course of business, not for control, suggesting a passive, potentially long-term investment perspective from a major asset manager.

Risks

• The document does not detail specific operational or financial risks related to Mirum Pharmaceuticals, Inc.
• As a passive investment (13G filing), Janus Henderson Group plc does not intend to influence control, which means there will be no active shareholder oversight or strategic intervention from this significant investor.

Management Comments

• Janus Henderson Group plc certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

Schedule 13G filings are standard disclosures by institutional investors like Janus Henderson Group plc, a global asset manager, to report passive ownership stakes exceeding 5% in publicly traded companies. This filing indicates a significant, non-controlling investment in Mirum Pharmaceuticals, Inc., a company operating within the pharmaceutical sector, reflecting a common portfolio management strategy.

Comparison to Industry Standards

• As a passive ownership disclosure, this filing does not provide performance metrics for direct comparison to industry standards or specific comparable companies.
• Institutional ownership by major asset managers like Janus Henderson is a standard practice in the investment industry, reflecting their portfolio management strategies across various sectors, including pharmaceuticals, and is consistent with typical investment firm behavior.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Janus Henderson Group plc may be viewed positively by other shareholders, potentially indicating confidence from a large, reputable investor.
• Management: As the investment is passive and not for control, there is no direct impact on Mirum Pharmaceuticals' management or operational strategies mentioned in this filing.

Key Dates

Keywords

Mirum Pharmaceuticals, Janus Henderson Group, SEC filing, Schedule 13G, beneficial ownership, institutional investment, common stock, pharmaceuticals, investment adviser, holding company